Stryker Co. (NYSE:SYK) Shares Purchased by Canopy Partners LLC

Canopy Partners LLC raised its position in Stryker Co. (NYSE:SYK) by 17.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,080 shares of the medical technology company’s stock after buying an additional 158 shares during the quarter. Canopy Partners LLC’s holdings in Stryker were worth $389,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of SYK. Rathbones Group PLC increased its stake in shares of Stryker by 5.0% during the fourth quarter. Rathbones Group PLC now owns 27,837 shares of the medical technology company’s stock worth $10,023,000 after acquiring an additional 1,332 shares during the period. Invesco Ltd. boosted its holdings in Stryker by 15.3% in the 4th quarter. Invesco Ltd. now owns 2,007,105 shares of the medical technology company’s stock valued at $722,658,000 after purchasing an additional 266,587 shares in the last quarter. Bank of Montreal Can increased its position in Stryker by 1.1% during the 4th quarter. Bank of Montreal Can now owns 549,836 shares of the medical technology company’s stock worth $197,969,000 after purchasing an additional 5,749 shares during the period. Trek Financial LLC raised its stake in shares of Stryker by 770.5% during the 4th quarter. Trek Financial LLC now owns 9,967 shares of the medical technology company’s stock worth $3,589,000 after buying an additional 8,822 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Stryker by 10.0% in the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock valued at $2,892,946,000 after buying an additional 727,850 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on SYK shares. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. Barclays boosted their price objective on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Royal Bank of Canada increased their target price on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Argus set a $450.00 price target on Stryker in a research note on Monday, February 3rd. Finally, Stifel Nicolaus upped their price target on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Price Performance

SYK stock opened at $346.14 on Monday. The stock has a market capitalization of $132.12 billion, a price-to-earnings ratio of 44.61, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The stock’s fifty day simple moving average is $381.69 and its 200-day simple moving average is $374.39. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company posted $3.46 EPS. Equities research analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.97%. Stryker’s payout ratio is 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.